Key Points
- Omada Health President Wei-Li Shao sold 8,866 shares for approximately $221,827 at an average price of $25.02, reducing his direct stake by 2.8% to 307,372 shares.
- Omada exceeded second-quarter expectations, reporting $0.08 in EPS versus an anticipated $0.02 loss and revenue of $87.83 million versus estimates of $80.93 million.
- Analysts maintain a generally positive outlook, with an average “Moderate Buy” rating and a price target around $25.75, though the stock’s valuation above 475 times earnings and recent executive selling could weigh on sentiment.
Omada Health, Inc. (NASDAQ:OMDA - Get Free Report) CAO Craig Gracey sold 1,042 shares of the stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $25.00, for a total transaction of $26,050.00. Following the completion of the sale, the chief accounting officer directly owned 15,441 shares of the company's stock, valued at $386,025. This represents a 6.32% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.
Craig Gracey also recently made the following trade(s):
- On Wednesday, July 1st, Craig Gracey sold 637 shares of Omada Health stock. The stock was sold at an average price of $23.00, for a total transaction of $14,651.00.
- On Tuesday, June 30th, Craig Gracey sold 405 shares of Omada Health stock. The shares were sold at an average price of $22.00, for a total transaction of $8,910.00.
- On Monday, June 29th, Craig Gracey sold 2,083 shares of Omada Health stock. The stock was sold at an average price of $21.00, for a total transaction of $43,743.00.
- On Friday, June 26th, Craig Gracey sold 2,084 shares of Omada Health stock. The stock was sold at an average price of $20.00, for a total transaction of $41,680.00.
- On Wednesday, June 24th, Craig Gracey sold 2,083 shares of Omada Health stock. The stock was sold at an average price of $19.01, for a total transaction of $39,597.83.
- On Monday, June 22nd, Craig Gracey sold 2,083 shares of Omada Health stock. The shares were sold at an average price of $18.00, for a total transaction of $37,494.00.
- On Friday, June 12th, Craig Gracey sold 6,894 shares of Omada Health stock. The shares were sold at an average price of $17.42, for a total transaction of $120,093.48.
Omada Health Stock Performance
OMDA opened at $23.84 on Thursday. The stock has a market cap of $1.46 billion, a price-to-earnings ratio of 476.80 and a beta of 1.73. The firm's fifty day moving average is $20.74 and its 200 day moving average is $16.38. Omada Health, Inc. has a fifty-two week low of $10.28 and a fifty-two week high of $26.92.
Omada Health (NASDAQ:OMDA - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported $0.08 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.02) by $0.10. The business had revenue of $87.83 million during the quarter, compared to analyst estimates of $80.93 million. Omada Health had a return on equity of 2.67% and a net margin of 1.39%. On average, equities research analysts predict that Omada Health, Inc. will post -0.01 earnings per share for the current year.
Analysts Set New Price Targets
Several research firms recently issued reports on OMDA. Weiss Ratings upgraded Omada Health from a "sell (e+)" rating to a "sell (d+)" rating in a research report on Tuesday. BMO Capital Markets reissued an "outperform" rating and issued a $24.00 price target on shares of Omada Health in a report on Friday, August 7th. Needham & Company LLC restated a "buy" rating and issued a $28.00 price target on shares of Omada Health in a research note on Friday, May 8th. Robert W. Baird increased their price objective on shares of Omada Health from $15.00 to $25.00 and gave the company a "neutral" rating in a report on Wednesday. Finally, The Goldman Sachs Group reiterated a "buy" rating on shares of Omada Health in a research report on Friday, May 8th. Eleven investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $25.75.
Get Our Latest Research Report on OMDA
Omada Health News Roundup
Here are the key news stories impacting Omada Health this week:
- Positive Sentiment: Q2 earnings beat expectations. Omada reported earnings of $0.08 per share, compared with the consensus estimate of a $0.02 loss. Revenue reached approximately $87.8 million, exceeding estimates of $80.9 million. The results indicate that growth in the company’s digital chronic-care business is increasingly translating into profitability. Omada Health Q2 earnings analysis
- Positive Sentiment: Analysts raised their price targets. Robert W. Baird increased its target from $15 to $25 while maintaining a neutral rating. Other recent targets include $27 from Citizens JMP and $35 from BTIG, supporting a broader consensus “Moderate Buy” rating with an average target near $25.67.
- Positive Sentiment: Institutional interest has expanded. Perceptive Advisors and BlackRock established new positions during the second quarter, while Millennium Management significantly increased its stake. These investments may provide support by signaling growing institutional confidence in Omada’s outlook.
- Neutral Sentiment: Short interest is effectively nonexistent. Reported short interest was zero shares, offering no meaningful short-covering catalyst but also indicating limited bearish positioning.
- Negative Sentiment: Several senior executives sold shares. CEO Sean Duffy sold 21,570 shares across two transactions, CFO Steven Cook sold 16,842 shares, President Wei-Li Shao sold 8,866 shares, and Chief Accounting Officer Craig Gracey sold 1,042 shares. The sales totaled approximately $1.16 million, mostly near $25 per share. Although the transactions may reflect personal liquidity or compensation planning, concentrated selling by top executives can weigh on investor sentiment.
- Negative Sentiment: Valuation leaves little room for disappointment. Omada’s market capitalization is approximately $1.46 billion and its reported price-to-earnings ratio is above 475. With shares near the top of their 52-week range, investors may be taking profits despite the earnings beat, particularly while analysts such as Baird remain neutral.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Quarry LP purchased a new position in shares of Omada Health during the fourth quarter valued at about $29,000. TD Waterhouse Canada Inc. purchased a new stake in shares of Omada Health in the fourth quarter worth about $32,000. Raymond James Financial Inc. purchased a new stake in shares of Omada Health in the second quarter worth about $32,000. Inlight Wealth Management LLC bought a new position in Omada Health during the fourth quarter valued at approximately $45,000. Finally, Versant Capital Management Inc boosted its stake in Omada Health by 319.3% during the second quarter. Versant Capital Management Inc now owns 2,998 shares of the company's stock valued at $66,000 after buying an additional 2,283 shares during the last quarter.
Omada Health Company Profile
(
Get Free Report)
Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company's platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.
In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
